TABLE 1.
Key data in CONTINUUM.
| Variable | Baseline value (range) | References | Distribution |
|---|---|---|---|
| EFS survival model | |||
| Sintilimab group | Shape = 0.7947444, Scale = 0.0081186 | Liu et al. (2024) | - |
| Standard therapy group | Shape = 1.2297630, Scale = 0.0025608 | Liu et al. (2024) | - |
| OS survival model | |||
| Sintilimab group | Shape = 1.1514328, Scale = 0.0011003 | Liu et al. (2024) | - |
| Standard therapy group | Shape = 2.214, Scale = 0.00001507 | Liu et al. (2024) | - |
| Risk for main adverse events in Sintilimab group | |||
| Anaemia | 0.16 | Liu et al. (2024) | Beta |
| Leukopenia | 0.25 | Liu et al. (2024) | Beta |
| Nausea | 0.14 | Liu et al. (2024) | Beta |
| Mucositis | 0.33 | Liu et al. (2024) | Beta |
| Anorexia | 0.10 | Liu et al. (2024) | Beta |
| Neutropenia | 0.21 | Liu et al. (2024) | Beta |
| Dermatitis | 0.04 | Liu et al. (2024) | Beta |
| Fatigue | 0.07 | Liu et al. (2024) | Beta |
| Vomiting | 0.11 | Liu et al. (2024) | Beta |
| Risk for main adverse events in standard therapy group | |||
| Anaemia | 0.11 | Liu et al. (2024) | Beta |
| Leukopenia | 0.22 | Liu et al. (2024) | Beta |
| Nausea | 0.15 | Liu et al. (2024) | Beta |
| Mucositis | 0.30 | Liu et al. (2024) | Beta |
| Anorexia | 0.07 | Liu et al. (2024) | Beta |
| Neutropenia | 0.18 | Liu et al. (2024) | Beta |
| Dermatitis | 0.03 | Liu et al. (2024) | Beta |
| Vomiting | 0.11 | Liu et al. (2024) | Beta |
Abbreviation: EFS, event-free survival; OS, overall survival.